The German unit of Immunic Inc has received a loan of up to €24.5 million from the European Investment Bank to support development of its lead asset as a potential treatment for patients with moderate coronavirus disease. The small molecule drug, IMU-838 (vidofludimus calcium), is also being tested in Phase 2 trials as a treatment for chronic inflammatory and autoimmune diseases, including multiple sclerosis and ulcerative colitis.
